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BACKGROUND: Familial hypercholesterolemia (FH) is an
autosomal-dominant disorder caused by mutations in 1
of 3 genes. In the 60% of patients who are mutation neg-
ative, we have recently shown that the clinical phenotype
can be associated with an accumulation of common
small-effect LDL cholesterol (LDL-C)-raising alleles by
use of a 12–single nucleotide polymorphism (12-SNP)
score. The aimsof the studywere to improve the selection
of SNPs and replicate the results in additional samples.
METHODS: We used ROC curves to determine the opti-
mum number of LDL-C SNPs. For replication analysis,
we genotyped patients with a clinical diagnosis of FH
from6countries for 6LDL-C-associated alleles.We com-
pared theweightedSNP score amongpatientswithno con-
firmed mutation (FH/M–), those with a mutation (FH/
M), and controls fromaUKpopulation sample (WHII).
RESULTS: Increasing the number of SNPs to 33 did not
improve the ability of the score to discriminate be-
tween FH/M– and controls, whereas sequential re-
moval of SNPs with smaller effects/lower frequency
showed that a weighted score of 6 SNPs performed as
well as the 12-SNP score. Metaanalysis of the weighted
6-SNP score, on the basis of polymorphisms inCELSR2
(cadherin, EGF LAG 7-pass G-type receptor 2), APOB
(apolipoprotein B), ABCG5/8 [ATP-binding cassette,
sub-familyG (WHITE),member 5/8], LDLR (lowden-
sity lipoprotein receptor), and APOE (apolipoprotein
E) loci, in the independent FH/M– cohorts showed a
consistently higher score in comparison to the WHII
population (P 2.2 1016).Modeling in individuals
with a 6-SNP score in the top three-fourths of the score
distribution indicated a 95% likelihood of a poly-
genic explanation of their increased LDL-C.
CONCLUSIONS: A 6-SNP LDL-C score consistently dis-
tinguishes FH/M– patients from healthy subjects. The
hypercholesterolemia in 88%ofmutation-negative pa-
tients is likely to have a polygenic basis.
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Familial hypercholesterolemia (FH),16 in its classic
form, appears to be an autosomal-codominant disor-
der, characterized by increased plasma concentrations
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of LDL cholesterol (LDL-C) and premature symptoms
of coronary heart disease (CHD) (1 ). The prevalence of
heterozygous FH is 0.2%–0.5% (1, 2 ), with a higher
prevalence in some populations due to founder effects
(2 ). Worldwide, 14–34 million people are thought to
be affected with heterozygous FH, of whom at least
95% are undiagnosed (2 ). Clinical diagnostic systems
for FH have been developed in the UK (3 ), the US (4 ),
and the Netherlands (5 ). On the basis of the degree of
increase in LDL-C concentrations (typically 189
mg/dL or4.9 mmol/L in adults) and a family history
of early CHD and/or increased cholesterol concentra-
tions, such patients are given a diagnosis of possible FH
(PFH). The additional presence of clinical features,
such as tendon xanthomas, results in a diagnosis of
definite FH (DFH). When patients carry variants
deemed to be pathogenic, they also receive DFH as di-
agnosis. The usefulness of a molecular test to provide an
unequivocal diagnosis is becoming increasingly appreci-
ated, inparticular toenhanceunambiguous identification
of affected relatives (6). Early identification of at-risk in-
dividuals allows changes in lifestyle including dietary in-
tervention and drug treatment, usually with one of the
statin class of lipid-lowering agents, which have been
shown to significantly reduce coronary atherosclerosis
(7) and improve life expectancy (8, 9).
Since 2008, several guidelines for the identification
and management of patients with FH have been pub-
lished (10–13). Although they differ in detail and em-
phasis, there are several common threads (reviewed in
(14)), including the utility of genetic testing to confirm
the diagnosis and apply it in cascade testing of the rel-
atives, which is a cost-effective approach to find new
cases (15–17). Cascade testing has been used exten-
sively in several countries in Europe, most notably in
the Netherlands (6 ), where it has resulted in the iden-
tification of 67% of FH patients with an assumption of
1:450 prevalence (18), which is probably underesti-
mated (19, 20). The UK guidelines (10) state that cas-
cade testing of first-degree relatives of every FH pro-
band should be carried out where a mutation has
been identified in the proband, or if nomutation can be
identified, on the basis of LDL-C measures. However,
in the Netherlands, cascade testing is carried out only
in families in which amutation has been identified (6 ),
and this approach is also being adopted in Wales (21).
FH is caused by mutations in LDLR (low density
lipoprotein receptor),17 APOB (apolipoprotein B), or
PCSK9 (proprotein convertase subtilisin/kexin type 9)
(1, 2 ). The most common class of genetic defect is a
mutation in LDLR, and currently 1200 mutations
have been reported worldwide (http://www.ucl.ac.uk/
fh) (22). Even with exhaustive screening, in a small
proportion of DFH subjects (10%–15%) with tendon
xanthomas and a larger proportion of PFH patients
(60%–75%), no mutation can be found (e.g., (23)).
This may be for several reasons, for instance: failure to
detect all DNA changes present by use of currentmeth-
ods, the mutations being in genetic regions that are
not currently covered (e.g., introns), or the muta-
tions being in genes that are yet to be identified as
causing FH. However, the most likely reason is the in-
clusion of non-FHpatients (i.e., a clinical false-positive
diagnosis).
In 2010, metaanalysis of genome-wide association
study (GWAS) data identified 95 loci involved in de-
termining lipid concentrations (24), and we have used
a 12–single nucleotide polymorphism (12-SNP) LDL-
C genetic risk score (the weighted sum of the LDL-C-
raising alleles, where weights are the effect sizes from
GWAS) as an unbiased genetic instrument for Mende-
lian randomization studies (25 ). Compared with
3000 subjects from the UK population–based
Whitehall II (WHII) study, the weighted LDL-C-
raising SNP score frequency distribution among UK
FH patients with no identified mutation (FH/M–) was
significantly higher (P  4.5  1016), an effect that
was confirmed in a cohort of similar patients from Bel-
gium. This strongly suggests that a substantial propor-
tion of FH/M– patients (up to 20%) are likely to have a
polygenic cause of the increase in LDL-C rather than an
as yet unknown single-gene mutation. Cascade testing
is likely to be less effective in such cases, since fewer
than the predicted 50% of first-degree relatives will
have inherited enough of the polygenes to have con-
centrations of LDL-C above the diagnostic threshold
(26).
In the current article, we have examined the pos-
sibility of using additional SNPs to improve discrimi-
nation and fewer SNPs to reduce genotyping costs; we
have examined the utility of the LDL-C SNPs score in
an additional 7 cohorts (from 6 countries) of patients
with a clinical diagnosis of FH; and we have estimated
the likelihood of having a polygenic (as opposed to a
monogenic) cause of hypercholesterolemia.
Methods
SELECTION AND GENOTYPING OF LDL-C GENETIC RISK
SCORE SNPs
We performed LDL-C genetic score variant selection
analysis with the WHII cohort (25) and the FH/M–
patients (n  175) (Oxford familial hypercholesterol-
17 Human genes: LDLR, low density lipoprotein receptor; APOB, apolipoprotein B;
PCSK9, proprotein convertase subtilisin/kexin type 9; CETP, cholesteryl ester
transfer protein, plasma; CELSR2, cadherin, EGF LAG 7-pass G-type receptor 2;
ABCG5/8, ATP-binding cassette, sub-family G (WHITE), member 5/8; APOE,
apolipoprotein E.
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emia study, (27) and (28)). We added 21 additional
meta-GWAS LDL-C-associated SNPs (see Supplemen-
tal Table 1, which accompanies the online version of
this article at http://www.clinchem.org/content/vol61/
issue1) (24) to the original 12-SNP score. Genotypes
were obtained with the Metabochip (Illumina) geno-
typing array. We included all SNPs in regression mod-
els for LDL-C and used the best-fitting sets of SNPs
determined by the lowest Akaike information criterion
(AIC) and Bayesian information criterion (BIC) to
construct 2 additional scores. We assessed the discrim-
inatory ability of these scores using the area under the
ROC. The original 12 SNPs in the score were ranked by
their frequency and effect size, and the top 6 SNPs were
selected for score calculations. We used ROC curves to
evaluate the sensitivity/specificity of using a 12- vs
6-SNP score in discriminating between a general pop-
ulation and FH patients with no mutation (performed
on cohorts from the original study (25)).
We performed genotyping with KASPar PCR
TaqMan assays (Life Technologies) and genotype call-
ing with an automated system, the results of which
were checked manually by study personnel with
SNPviewer software. One SNP (rs4299376) could not
be genotyped byTaqMan, and a proxywas used instead
(rs6544731).
PATIENT COHORTS
We collected 7 independent cohorts of patients diag-
nosedwith FH. Informedwritten consentwas obtained
from all subjects, and the study was approved by ethics
committees in each county. The biggest cohort com-
prised 638 Dutch adults, which included 66 mutation-
positive (FH/M) and 572 FH/M– patients. Other co-
horts included 128Greek children (68 FH/M, 60 FH/
M–), 22 Dutch children (all mutation FH/M–), 76
adults from Canada (39 mutation FH/M, 37 FH/
M–), 202 adults from Italy (144 FH/M, 58 FH/M–),
29 adults fromPoland (14 FH/M, 15 FH/M–), and 63
adults from Israel (20 FH/M, 43 FH/M–). All indi-
viduals were of white background. All subjects had an
autosomal-dominant mode of inheritance of hyper-
cholesterolemia in the family; the presence of primary
hypercholesterolemia [total cholesterol (TC) 290
mg/dL or 7.5 mmol/L (or TC 259 mg/dL or 6.7
mmol/L for children16 years of age)] in the proband
or proband’s first-degree relative; plasma or serum
LDL-C189 mg/dL or4.9 mmol/L; and family his-
tory of coronary artery disease at 55 years for men
and60 years for women in a first-degree relative. In
addition, some subjects had a personal or a family his-
tory of tendon and cutaneous xanthomas. Patients
from Israel were clinically diagnosed with the Make
Early Diagnosis Prevent Early Death (MED-PED) cri-
teria (4 ). The FH mutation detection methods varied
slightly; however, they all included screening of the en-
tire coding region of LDLR. The samples were also
tested for APOB p.R3527Q (apart from the Greek co-
hort, since the mutation has never been found in
Greece) and PCSK9 p.D374Y.
SNP SCORE CALCULATIONS IN REPLICATION COHORTS
The LDL-C SNP score was calculated with weighted
sums for the 6 selected SNPs. We used a group of 3020
healthy individuals (participants of the WHII study
(29)) for comparison (baseline characteristics ofWHII
are shown in online Supplemental Table 2).
ESTIMATING THE PROBABILITY OF A POLYGENIC CAUSE
Given an individual who is diagnosed with FH but for
whom no causal mutation has been found in the
known FH genes, we assume that the LDL-C is 189
mg/dL or 4.9 mmol/L either because of an unknown
single-gene mutation or a polygenic cause. For such
individuals, we can use the equation below to calculate
the probability of a polygenic cause (explained further
in online Supplemental Methods):
P x  ve LDL 189,g,m  ve	

PLDL 189 x  ve,g	  P x  ve m  ve	

xPLDL 189 x,g	  P x m  ve	
The relative probability of these 2 causes depends
on the frequency of unknown single gene mutations
and the probability distribution of the polygenic ef-
fects. Given these, it is straightforward to work out the
probability of a polygenic cause given an individual’s
mutational status at the known FH genes, LDL-Cmea-
surement, and polygenic score. However, we do not
know either the true polygenic score (since not all the
LDL-C genes have been found) or the frequency of un-
known single-gene mutations (by definition). Here we
approximate the polygenic term by use of the effects of
the 6-SNP score in WHII individuals and calculate the
probability for several different unknown mutation
frequencies (0, 0.001, 0.005, 0.01). Note that, if we as-
sume the frequency of confirmed FH is 1/500 0.002,
when we have found all of the LDLR/APOB/PCSK9
mutations, the prevalence of undetected monogenic
mutations must be 0.002. Also note that use of the
6-SNP genetic risk score underestimates the role of
the polygenic component and so will underestimate
the probability of a polygenic cause.
Results
PATIENT BASELINE CHARACTERISTICS
The baseline characteristics of the FH patients in-
cluded in this study are shown in online Supplemen-
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tal Table 3. Overall, in all cohorts where data was
available, FH/M patients had higher pretreatment
TC and LDL-C than FH/M– patients from the same
cohort.
VARIANT SELECTION
We first attempted to improve the performance of the
SNP score by including 21 additional SNPs (online
Supplemental Table 1), previously identified by the
Global Lipid Genetics Consortium GWAS metaanaly-
sis as influencing LDL-C (24). Tomaintain a high spec-
ificity for LDL-C, we had originally included SNPs
whose only or major effect was on LDL-C and not on
another lipid trait, but for this analysis the additional
genes [e.g., CETP (cholesteryl ester transfer protein,
plasma)] included affected lipid traits other than
LDL-C.
Addition of these 21 LDL-C-raising SNPs did not
significantly improve the ability of the SNP score to
discriminate between FH/M– and healthy subjects
(AROC  0.673, 95% CI 0.632–0.715, P  0.98) (see
online Supplemental Fig. 1). BIC analysis selected 13
SNPs for the score (6 SNPs from the original 12-SNP
score and 7 GWAS SNPs of the additional 21) (see on-
line Supplemental Table 4). AIC analysis selected a 25-
SNP set (composed of 8 SNPs from the original 12
SNPs and 17 SNPs from the additional 21) (see online
Supplemental Table 5). Neither BIC nor AIC SNP se-
lections improved the performance of the 12-SNP
score (see online Supplemental Fig. 1). After this, the
sequential removal of SNPs of smaller effects and/or
lower minor allele frequencies showed that a weighted
score of 6 SNPs performed as well as the 12-SNP score
(P 0.16) (Fig. 1). Thus, to improve the cost-efficiency
of the study, the SNP score calculations in the replica-
tion cohorts were based on genotypes of 6 SNPs
[nearby gene]: rs629301 [CELSR2 (cadherin, EGF LAG
7-pass G-type receptor 2)], rs1367117 [APOB],
rs6544713 [proxy of rs4299376, ABCG5/8 (ATP-
binding cassette, sub-family G (WHITE), member
5/8)], rs6511720 [LDLR], rs429358 [APOE (apolipo-
protein E)], and rs7412 [APOE], summarized in online
Supplemental Table 6. Genotypes for the 6-SNP score
were available in a total of 351 FH/M and 807 FH/M–
patients.
LDL-C SNP SCORE
Overall, the FH/M– group had the highest mean
LDL-C SNP score (0.708), followed by the FH patients
with an identified mutation (FH/M) (0.656). The
control WHII cohort had the lowest weighted score
(0.632), which was significantly lower than the FH/M–
(P 2.2 1016) and the FH/M (P 0.04) cohorts
(see online Supplemental Fig. 2). Among the FH/M–
patient cohorts, the highest LDL-C SNP score was ob-
served in Dutch children (0.782) followed by Greek
children (0.731) (see online Supplemental Table 7).
Among FH/M– patients, 707 (88%) of had a score
above the first quartile, of whom288 (36%of thewhole
FH/M– cohort) had a score that fell within the top
quartile of the WHII LDL-C SNP score distribution.
The FH/M patients were divided into LDLRmu-
tation carriers (n  323), APOB p.R3527Q (n  13)
carriers, and PCSK9 p.D374Y carriers (n 2). Patients
who had the APOB p.R3527Q mutation had signifi-
cantly lower LDL-C SNP score than patients with other
mutations (0.521 vs 0.661, P 0.05) (Fig. 2).
LDL-C SNP score results for each of the 7 cohorts
genotyped in this study were combined with 2 large
cohorts (from theUKSimonBroome register and from
Belgium) analyzed in the original study (25), for a
metaanalysis, shown in Fig. 3. Again the effect in all
cohorts was highly consistent, and the overall stan-
dardized mean difference for all FH/M– groups com-
pared with the WHII sample was 0.381 (95% CI
0.328–0.433).
ESTIMATION OF THE PROPORTION OF FH/M– SUBJECTS LIKELY
TO BE POLYGENIC BY SNP SCORE
For clinical utility, it would be valuable to estimate the
probability that the increased LDL-C seen in an FH/M–
individual can be explained by their weighted 6-SNP
score. The first estimate needed for this calculation is
the underlying rate of undetected monogenic muta-
tions in FH/M– subjects. On the basis of the lack of
novel genes causing FH reported to date, and in our
whole exome next-generation sequencing data of 70
Fig. 1. AROC analysis of the discrimination between
healthy individuals and FH-M/– patients by use of
12-SNP vs. 6-SNP LDL-C score.
There was no significant specificity/sensitivity difference
between the scores.
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FHno-mutation patients, which also failed to identify a
novel common FH-causing gene (30), this is a reason-
able estimate. By contrast, if we have identified only
75% of all mutations to be found, the frequency of the
remaining undetectedmutations would be 0.0005, and
this seems likely to be the upper limit of undetected
mutations. At an undetected mutation frequency of
0.0005, our analysis, shown in Fig. 4, suggests that the
probability of a polygenic cause for LDL 189 mg/dL
(4.9 mmol/L) in all the assessed FH/M– individuals is
95%, and it goes down when the frequency of unde-
tected monogenic cause increases (see online Supple-
mental Fig. 3).
Discussion
The LDL-C SNP score analysis in 7 independent co-
horts consistently confirmed the findings reported by
Talmud et al. (25), that patients with a clinical diagno-
sis of FH but with no identified mutation (FH/M–)
have a significantly higher mean LDL-C-raising SNP
score than individuals from the general population
(combined sample P  2.2  1016), which suggests
that their high plasma LDL-C concentrations are con-
siderably influenced by polygenes. In addition, as pre-
viously reported, FH patients who carry an FH-causing
mutation (FH/M) also had higher mean LDL-C SNP
scores than the WHII cohort (P  0.04), which con-
firms results from Talmud et al. (25) and suggests that
in at least some cases the FH phenotype is being caused
by the combination of a single mutation of large effect
and several LDL-C-raising alleles ofmodest effect. This
result could help to explain the variability in pen-
etrance of certain FH mutations in the relatives of FH
probands. When analyzing the mutation-positive pa-
tients by the mutated gene, patients with the defective
APOB (due to the p.R3527Qmutation) had the lowest
SNP score (0.521) among all studied groups. This sug-
gests that the APOB mutation is highly penetrant,
which is contradictory to what has been shown previ-
ously (31) and may reflect sample bias in this selected
group of FH patients. Another explanation is that not
all LDLR variants identified in the FH/M group are
truly pathogenic, which leads to misclassification. The
highest LDL-C SNP score was observed in the 2
mutation-negative hypercholesterolemic children co-
horts (1 from the Netherlands and 1 from Greece),
showing for the first time that the SNP score discrimi-
Fig. 2. Boxplot of the LDL-C-weighted SNP score in WHII control cohort and patients groups.
The patients who carried the APOB p.R3527Q mutation (n  13) had significantly lower SNP scores than patients with LDLR
and PCSK9 mutations (0.521 vs 0.661, P  0.05).
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nates well in children as well as adults. In general, the
mutation detection rate in children with a clinical di-
agnosis of FH is higher than in adults (32), and this is
because, when comparing the LDL-C distribution in
FH patients and their unaffected siblings, the false-
positive and false-negative rate is smaller in childhood
than in adulthood (26), where secondary environmen-
tal causes for high LDL-C concentrations may have an
influence. Our data suggest that in a child, once a
single-gene cause for having highly increased LDL-C is
ruled out, a polygenic cause is highly likely. However,
to confirm this result, the child cohorts should be com-
pared against a control of country-matched children
with homogeneous lifestyle backgrounds, which is cur-
rently unavailable and remains a limitation to this
study.
One of the limitations in the 6-SNP score we have
used here is that it does not contain all of the informa-
tion on the genetic determinants of LDL-C concentra-
tions available following the recent GWAS studies. If
patient samples are being tested with next-generation
sequencing approaches, it is technically and financially
feasible to include all 12 SNPs and indeed to include all
SNPs that have been associatedwith LDL-C even if they
also influence other lipid traits. From a diagnostic
point of view, we have shown that the 6-SNP score is as
good at discriminating between FH/M– and WHII
control subjects as the 12-SNP score, and a smaller
number of SNPs would clearly have cost benefits. We
show here that the 6-SNP score discriminates well in
FH patients from an additional 6 countries, but all
samples are from white patients and we currently have
nodata to allowus to extrapolate the utility of this score
to patients from other ethnic backgrounds, in whom
the minor allele frequency will differ considerably and
in whom the raising effect of the SNPs on LDL-C may
not be consistent. Another limitation may be that the
probability of having LDL-C 189 mg/dL (4.9
mmol/L) given the LDL-C genetic risk score was esti-
mated in the FH patients on the basis of a model with
observed LDL-C concentrations in the WHII cohort.
However, given the highmeanLDL-C concentration in
WHII, the estimated probability of having LDL-C
189mg/dL or4.9mmol/L is likely to be higher than
Fig. 3. Meta-analysis of the LDL-C SNP score in 9 independent FH mutation–negative cohorts in comparison to the
WHII population.
Highlighted in red box are 2 cohorts studied in the original report (25 ). The overall standardized mean difference was
0.381.
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that estimated in a younger, healthier sample. This will
translate into a lower probability of a polygenic cause,
especially for those in the lowest quartile of the genetic
risk score.
The question remains whether the mutation-
negative patients do indeed carry an unidentified FH-
causing mutation and, if so, what proportion this rep-
resents. Although we accept that this is a possibility, we
believe it will be a very rare event. The prior probability
that a patient with a clinical diagnosis of FH has a mu-
tation in 1 of the 3 known FH-causing genes is approx-
imately 80% (i.e., in those with the clinical diagnosis of
definite FH this is the mutation detection rate previ-
ously reported (3 )). To date, there have been no re-
ports of any identified fourth gene where mutations
cause autosomal-dominant FH. Once the presence of a
mutation in known genes is ruled out by comprehen-
sive molecular genetic diagnostic methods, the second
most likely probable cause, as we show here, is a poly-
genic inheritance. Our analysis here indicates that, as-
suming an undetected mutation frequency of 0.0005,
the probability of a polygenic cause for LDL-C 189
mg/dL (4.9 mmol/L) in the assessed FH/M– individu-
als is 95%. There is also a possibility that FH/M–
patients who have the LDL-C genetic risk score in the
lower quartiles of the score distribution have an inter-
mediate phenotype between FH and familial combined
hyperlipidemia, hence the slightly higher TG in FH/M–
patients. This could be due to inheritance of higher
numbers of LDL-C- and TG-raising alleles. Therefore,
as before (25), we believe that the clinical diagnosis of
FH should be used only for patients with a DNA-
identified genetic cause.
All recent guidelines for the diagnosis and cascade
testing of FH, except in the US, have recommended the
utility of DNA testing when the family mutation is
known and of LDL-C measures where the mutation is
not available (14). On the basis of the data we present
here, only in those probands with a confirmed mono-
genic cause will cascade testing be cost effective, be-
cause in the remainder there is most likely a polygenic
cause. In countries where DNA testing is not available
(for reasons of availability or willingness to fund such
genetic tests), cascade testing, on the basis of LDL-C
measures, will prove to be less effective than it could be.
These data support the approach taken in the Nether-
lands and Wales of using costly cascade testing re-
sources only in the families in which the proband has
an identified mutation, since in the majority (at least
75%, i.e., the top 3 quartiles of the 6-SNP score) of the
no-mutation patients, the most likely explanation for
their clinical diagnosis of FH is a polygenic cause. In
individuals with a clinical diagnosis of FH with a SNP
score in the lowest quartile, however, it is unlikely that
there is a polygenic cause, and although amutation in 1
of the 3 known FH genes may have been missed for
technical reasons, research to identify whether the in-
dividuals have a mutation in a yet-to-be-identified
gene would be valuable.
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